<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33573">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052219</url>
  </required_header>
  <id_info>
    <org_study_id>AN-IGN3331</org_study_id>
    <nct_id>NCT02052219</nct_id>
  </id_info>
  <brief_title>BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of blisibimod plus standard of care
      versus placebo plus standard of care alone on the proportion of subjects achieving
      improvement in renal disease parameters.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects to achieve the proteinuria threshold</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects who progress to end-stage renal disease</measure>
    <time_frame>approximately 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum immunoglobulins IgA, IgG and IgM, plasma cells and B cell subsets</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum creatinine</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in eGFR</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects requiring the addition of corticosteroid or other therapy</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>IgA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Blisibimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blisibimod</intervention_name>
    <description>Blisibimod administered subcutaneously</description>
    <arm_group_label>Blisibimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Biopsy-proven IgA nephropathy

          -  Proteinuria â‰¥ 2g/24hr or equivalent

          -  Receiving physician-directed optimized standard of care that includes ACEI and/or
             ARB.

          -  Estimated glomerular filtration rate (eGFR) &gt;40mL/min/1.73m2

        Exclusion Criteria:

          -  Clinical or histologic evidence of non-IgA-related glomerulonephritis

          -  IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring

          -  Meets eGFR criteria

          -  Malignancy within past 5 years

          -  Known to be positive for HIV and/or positive at the screening visit for hepatitis B,
             or hepatitis C

          -  Liver disease

          -  Neutropenia

          -  Active infection requiring hospitalization or treatment with parenteral antibiotics
             within the past 60 days or history of repeated herpetic viral infections

          -  History of active tuberculosis or a history of tuberculosis infection

          -  Pregnant or nursing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>January 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blisibimod</keyword>
  <keyword>IgA nephropathy</keyword>
  <keyword>BAFF</keyword>
  <keyword>BLyS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
